Cerebrolysin in patients with acute ischemic stroke in Asia: Results of a double-blind, placebo-controlled randomized trial

Stroke

Volumn 43, Issue 3, 2012, Pages 630-636

  Heiss, Wolf Dieter ^a   Brainin, Michael ^b   Bornstein, Natan M ^c   Tuomilehto, Jaakko ^d   Hong, Zhen ^e  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b DANUBE UNIVERSITY KREMS   (Austria)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF HELSINKI   (Finland)

^e FUDAN UNIVERSITY   (China)

Author keywords

acute ischemic stroke; Cerebrolysin; clinical trial; neuroprotectants; stroke severity

Indexed keywords

ACETYLSALICYLIC ACID; CEREBROLYSIN; SODIUM CHLORIDE;

ACUTE BRAIN DISEASE; ACUTE ISCHEMIC STROKE; AGED; ARTICLE; ASIA; BARTHEL INDEX; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; ASIA; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; QUESTIONNAIRES; SAMPLE SIZE; STROKE; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857642810     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.628537     Document Type: Article

References (27)

1. Davis S, Lees K, Donnan G. Treating the acute stroke patient as an emergency: current practices and future opportunities. Int J Clin Pract. 2006;60:399-407.
2. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Neurol. 2003;5:367-375.
3. Fisher M. Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke. 2003;34:1539-1546.
4. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001;32:1598-1606.
5. Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging. 2007;28:1148-1162.
6. Tatebayashi Y, Lee MH, Li L, Iqbal K, Grundke-Iqbal I. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathol. 2003;105:225-232.
7. Gutmann B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R. In vitro models of brain ischemia: the peptidergic drug Cerebrolysin protects cultured chick cortical neurons from cell death. Neurotox Res. 2002;4:59-65.
8. Schauer E, Wronski R, Patockova J, Moessler H, Doppler E, Hutter-Paier B, et al. Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. J Neural Transm. 2006;113:855-868.
9. Riley C, Hutter-Paier B, Windisch M, Doppler E, Moessler H, Wronski R. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J Neural Transm. 2006;113:103-110.
10. Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci. 2007;25:25-31.
11. Hanson LR, Liu XF, Ross TM, Doppler E, Zimmermann-Meinzingen S, Moessler H, et al. Cerebrolysin reduces infarct volume in a rat model of focal cerebral ischemic damage. Am J Neuroprotec Neuroregen. 2009;1:62-68.
12. Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 2010;88:3275-3281.
13. Ladurner G, Kalvach P, Mössler H; Cerebrolysin Study Group. Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm. 2005;112:415-428.
14. Haffner Z, Gmeinbauer R, Moessler H. A randomized, double-blind, placebo-controlled trial with cerebrolysin in acute ischemic stroke [Abstract]. Cerebrovasc Dis. 2001;11:76.
15. Skvortsova VI, Stakhovskaia LV, Gubskii LV, Shamalov NA, Tikhonova IV, Smychkov AS. A randomized, doubleblind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2004; Suppl 11:51-55.
16. Hong Z, Moessler H, Bornstein N, Brainin M, Heiss WD; CASTAInvestigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with Acute ischaemic Stroke in Asia-CASTA. Int J Stroke. 2009;4:406-412.
17. ICH Topic E9, Statistical Principles for Clinical Trials, Step 4, Consensus guideline, February 5, 1998, CPMP/ICH/363/96. Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacyguidelines.html. Accessed January 19, 2012.
18. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke. 1996;27:2136-2142.
19. Wei LJ, Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multi-variate observations. J Am Stat Assoc. 1984;79:653-661.
20. Lachin JM. Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med. 1992;11:1151-1170.
21. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G; on behalf of the study group. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke. 2008;39:1774-1778.
22. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med. 2008;359:1317-1329.
23. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
24. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
25. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
26. Shuaib A, Lees K, Lyden P, Grotta J, Davalos A, Davis S, et al; for the SAINT II Investigators. NXY-059 for acute ischaemic stroke: results of the SAINT II trial. N Engl J Med. 2007;357:562-571.
27. Weimar C, Ho TW, Katsarava Z, Diener HC. Improving patient selection for clinical acute stroke trials. Cerebrovasc Dis. 2006;21:386-392.